Dr. Catherine S. Spina, MD, PhD

Dr. Spina practices at Columbia University Irving Medical Center in New York, New York.

Dr. Spina's NPI, 1417331737, was assigned on July 16, 2015. Dr. Spina graduated from Boston University School Of Medicine in 2015. Dr. Spina holds New York license 305743.

Dr. Spina's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 297-4255.

Dr. Spina's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Spina is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Spina to 1 more hospital and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spina practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Spina's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Spina is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Spina's licenses on file in 3 states: New York, Florida and Massachusetts.

Dmand AI lists bladder cancer radiation, bone cancer radiation, breast cancer radiation and prostate cancer radiation among the conditions Dr. Spina treats.

CMS data shows 683 Medicare services from Dr. Spina across 10 procedure codes in 2024, for 63 Medicare patients. Medicare paid $68,105 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 63 Medicare patients who saw Dr. Spina in 2024. The largest group is 75 to 84, with 27 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spina's median patient age at 73, with 21% women.

In 2024, Dr. Spina wrote 58 Medicare Part D claims for 26 patients. 100% of them were for generic drugs. CMS names the drug for 28 of them, across 1 drug with 11 or more claims each, at $347 in total drug cost. In 2023, CMS named 47 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Spina for performance year 2024, reported through an alternative payment model (APM). Dr. Spina accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spina as offering telehealth.

Dmand AI links 23 papers to Dr. Spina, published from 2013 to 2025. 2023 was the busiest year, with 3. The most frequent topics are Cell Line, Tumor, Kidney Neoplasms and Mice, Inbred BALB C. Dr. Spina has published most often in Adv Radiat Oncol. Dr. Spina's most frequent co-authors are Charles George Drake, MD, Israel Deutsch, MD and Matthew C. Dallos, MD.

CMS Open Payments shows 9 general payments to Dr. Spina from 4 drug and device companies from 2022 to 2024. Consulting fees make up the largest share, 67% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,170.

Dr. Spina graduated from Boston University School Of Medicine in 2015.

Dr. Spina is in network with 13 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.